341 related articles for article (PubMed ID: 33737437)
1. A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol.
Spierings J; van Rhenen A; Welsing PM; Marijnissen AC; De Langhe E; Del Papa N; Dierickx D; Gheorghe KR; Henes J; Hesselstrand R; Kerre T; Ljungman P; van de Loosdrecht AA; Marijt EW; Mayer M; Schmalzing M; Schroers R; Smith V; Voll RE; Vonk MC; Voskuyl AE; de Vries-Bouwstra JK; Walker UA; Wuttge DM; van Laar JM
BMJ Open; 2021 Mar; 11(3):e044483. PubMed ID: 33737437
[TBL] [Abstract][Full Text] [Related]
2. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.
van Laar JM; Farge D; Sont JK; Naraghi K; Marjanovic Z; Larghero J; Schuerwegh AJ; Marijt EW; Vonk MC; Schattenberg AV; Matucci-Cerinic M; Voskuyl AE; van de Loosdrecht AA; Daikeler T; Kötter I; Schmalzing M; Martin T; Lioure B; Weiner SM; Kreuter A; Deligny C; Durand JM; Emery P; Machold KP; Sarrot-Reynauld F; Warnatz K; Adoue DF; Constans J; Tony HP; Del Papa N; Fassas A; Himsel A; Launay D; Lo Monaco A; Philippe P; Quéré I; Rich É; Westhovens R; Griffiths B; Saccardi R; van den Hoogen FH; Fibbe WE; Socié G; Gratwohl A; Tyndall A;
JAMA; 2014 Jun; 311(24):2490-8. PubMed ID: 25058083
[TBL] [Abstract][Full Text] [Related]
3. Outcomes linked to eligibility for stem cell transplantation trials in diffuse cutaneous systemic sclerosis.
Spierings J; Nihtyanova SI; Derrett-Smith E; Clark KEN; van Laar JM; Ong V; Denton CP
Rheumatology (Oxford); 2022 May; 61(5):1948-1956. PubMed ID: 34314500
[TBL] [Abstract][Full Text] [Related]
4. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial.
Burt RK; Shah SJ; Dill K; Grant T; Gheorghiade M; Schroeder J; Craig R; Hirano I; Marshall K; Ruderman E; Jovanovic B; Milanetti F; Jain S; Boyce K; Morgan A; Carr J; Barr W
Lancet; 2011 Aug; 378(9790):498-506. PubMed ID: 21777972
[TBL] [Abstract][Full Text] [Related]
5. A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol.
van Rhijn-Brouwer FCC; Gremmels H; Fledderus JO; Schuurman AH; Bonte-Mineur F; Vonk MC; Voskuyl AE; de Vries-Bouwstra JK; Coert JH; Radstake TRDJ; van Laar JM; Verhaar MC;
BMJ Open; 2018 Aug; 8(8):e020479. PubMed ID: 30127049
[TBL] [Abstract][Full Text] [Related]
6. Autologous stem cell transplantation improves microcirculation in systemic sclerosis.
Miniati I; Guiducci S; Conforti ML; Rogai V; Fiori G; Cinelli M; Saccardi R; Guidi S; Bosi A; Tyndall A; Matucci-Cerinic M
Ann Rheum Dis; 2009 Jan; 68(1):94-8. PubMed ID: 18308744
[TBL] [Abstract][Full Text] [Related]
7. [The treatment of diffuse cutaneous systemic sclerosis with autologous hemopoietic stem cells transplantation (HSCT): our experience on 2 cases].
Miniati I; Saccardi R; Pagliai F; Guiducci S; Bosi A; Guidi S; Urbani S; Tyndall A; Matucci Cerinic M
Reumatismo; 2005 Dec; 57(4):277-82. PubMed ID: 16380756
[TBL] [Abstract][Full Text] [Related]
8. CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I/II clinical trial conducted in Japan.
Ayano M; Tsukamoto H; Mitoma H; Kimoto Y; Akahoshi M; Arinobu Y; Miyamoto T; Horiuchi T; Niiro H; Nagafuji K; Harada M; Akashi K
Arthritis Res Ther; 2019 Jan; 21(1):30. PubMed ID: 30670057
[TBL] [Abstract][Full Text] [Related]
9. Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more naïve state in patients with systemic sclerosis.
Adamska JZ; Zia A; Bloom MS; Crofford LJ; Furst DE; Goldmuntz E; Keyes-Elstein L; Mayes MD; McSweeney P; Nash RA; Pinckney A; Welch B; Love ZZ; Sullivan KM; Robinson W
Ann Rheum Dis; 2023 Mar; 82(3):357-364. PubMed ID: 36241361
[TBL] [Abstract][Full Text] [Related]
10. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of conventionally-treated systemic sclerosis patients eligible for autologous haematopoietic stem cell transplantation.
Panopoulos ST; Tektonidou MG; Bournia VK; Laskari K; Sfikakis PP
Clin Exp Rheumatol; 2021; 39 Suppl 131(4):29-33. PubMed ID: 33200737
[TBL] [Abstract][Full Text] [Related]
12. Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study.
Snowden JA; Hawkey C; Hind D; Swaby L; Mellor K; Emsley R; Mandefield L; Lee E; Badoglio M; Polge E; Labopin M; Gribben J; Pockley AG; Foulds GA; Lobo A; Travis S; Parkes M; Satsangi J; Papaioannou D; Lindsay JO; ;
BMC Gastroenterol; 2019 May; 19(1):82. PubMed ID: 31151436
[TBL] [Abstract][Full Text] [Related]
13. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
14. Autologous haematopoietic stem cell transplantation for Japanese patients with systemic sclerosis: Long-term follow-up on a phase II trial and treatment-related fatal cardiomyopathy.
Nakamura H; Odani T; Yasuda S; Noguchi A; Fujieda Y; Kato M; Oku K; Bohgaki T; Sugita J; Endo T; Teshima T; Atsumi T
Mod Rheumatol; 2018 Sep; 28(5):879-884. PubMed ID: 29251023
[TBL] [Abstract][Full Text] [Related]
15. Update on stem cell transplantation for systemic sclerosis: recent trial results.
Naraghi K; van Laar JM
Curr Rheumatol Rep; 2013 May; 15(5):326. PubMed ID: 23516015
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis.
Vonk MC; Marjanovic Z; van den Hoogen FH; Zohar S; Schattenberg AV; Fibbe WE; Larghero J; Gluckman E; Preijers FW; van Dijk AP; Bax JJ; Roblot P; van Riel PL; van Laar JM; Farge D
Ann Rheum Dis; 2008 Jan; 67(1):98-104. PubMed ID: 17526554
[TBL] [Abstract][Full Text] [Related]
17. [The arguments favoring autologous haematopoietic stem cell transplantation in systemic scleroderma].
Pugnet G
Rev Med Interne; 2024 Feb; 45(2):104-108. PubMed ID: 38267322
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease.
Binks M; Passweg JR; Furst D; McSweeney P; Sullivan K; Besenthal C; Finke J; Peter HH; van Laar J; Breedveld FC; Fibbe WE; Farge D; Gluckman E; Locatelli F; Martini A; van den Hoogen F; van de Putte L; Schattenberg AV; Arnold R; Bacon PA; Emery P; Espigado I; Hertenstein B; Hiepe F; Kashyap A; Kötter I; Marmont A; Martinez A; Pascual MJ; Gratwohl A; Prentice HG; Black C; Tyndall A
Ann Rheum Dis; 2001 Jun; 60(6):577-84. PubMed ID: 11350846
[TBL] [Abstract][Full Text] [Related]
19. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis.
Burt RK; Oliveira MC; Shah SJ; Moraes DA; Simoes B; Gheorghiade M; Schroeder J; Ruderman E; Farge D; Chai ZJ; Marjanovic Z; Jain S; Morgan A; Milanetti F; Han X; Jovanovic B; Helenowski IB; Voltarelli J
Lancet; 2013 Mar; 381(9872):1116-24. PubMed ID: 23363664
[TBL] [Abstract][Full Text] [Related]
20. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study.
Farge D; Marolleau JP; Zohar S; Marjanovic Z; Cabane J; Mounier N; Hachulla E; Philippe P; Sibilia J; Rabian C; Chevret S; Gluckman E;
Br J Haematol; 2002 Dec; 119(3):726-39. PubMed ID: 12437652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
